SCHEMBL3337530

SCHEMBL3337530

CN(Nc1nc(-c2ccc([N+](=O)[O-])cc2)cs1)C(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.57
MAPT P10636 8/20 0.56
NPC1 O15118 1/20 0.56
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
POLB P06746 3/20 0.54
LMNA P02545 2/20 0.54
ALDH1A1 P00352 3/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
HTT P42858 1/20 0.53
GAA P10253 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
BAZ1A Q9NRL2 1/20 0.50
GFER P55789 1/20 0.49
CSNK2A1 P68400 1/20 0.49
ADORA3 P0DMS8 1/20 0.48
MAOA P21397 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12021534 0.86 CSNK2A1 (0.52) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL3341845 0.80 MAPT (0.60) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL3342093 0.80 MAPT (0.72) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL4732495 0.78 MAPT (0.56) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL10965903 0.75 RAB9A (0.78) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL9621679 0.74 RAB9A (1.00) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL10922446 0.73 RAB9A (0.80) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL10812081 0.73 RAB9A (0.80) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL12643697 0.73 MAPT (1.00) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL11481099 0.73 RAB9A (0.74) RAB9AMAPTNPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA RAB9A 2591/4885MAPT 2/4885NPC1 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.